Human medicines European public assessment report (EPAR): Xadago, safinamide, Parkinson Disease, Date of authorisation: 23/02/2015, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Mounjaro, tirzepatide, Diabetes Mellitus, Type 2, Date of authorisation: 15/09/2022, Revision: 3, Status: Authorised

Appendix, on disclosure rules, to the functional specifications for the EU portal and EU database to be audited

Questions and answers on public consultation on implementation of transparency requirements of the European Clinical Trial Regulation

Draft proposal for an addendum, on transparency, to the 'functional specifications for the European Union (EU) portal and EU database to be audited'

Human medicines European public assessment report (EPAR): Piqray, alpelisib, Breast Neoplasms, Date of authorisation: 27/07/2020, Revision: 10, Status: Authorised

Sixth Nitrosamine Implementation Oversight Group (NIOG) - meeting with pharmaceutical industry, from 07/12/2023 to 07/12/2023

Sixth Nitrosamine Implementation Oversight Group (NIOG) , from 07/12/2023 to 07/12/2023

Twelfth Nitrosamine Implementation Oversight Group (NIOG) meeting, from 06/12/2023 to 06/12/2023

Opinion/decision on a Paediatric investigation plan (PIP): Lanthanum carbonate hydrate, decision type: , therapeutic area: , PIP number: P/0507/2022